Marina Biotech Appoints Robert Moscato to Chief Executive Officer

City of Industry, CA, June 20, 2018 — Marina Biotech, Inc. (OTCQB: MRNA), a commercial stage pharmaceutical company focused on the development and commercialization of innovative therapeutics for hypertension, arthritis, pain and oncology, today announced that its Board of Directors has appointed Robert C. Moscato, Jr. to serve as Chief Executive Officer of the Company. Read More

Marina Biotech Announces a New Publication on Prestalia®

City of Industry, CA – February 27, 2018 – Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for hypertension, arthritis, pain and oncology, announced today further progress with its FDA-Approved Prestalia® hypertension drug, with the issuance of a new and independent publication on Prestalia®:  Elliott WJ Read More

Marina Biotech Announces Agreement for Drug Development and Licensing with Autotelic Bio

City of Industry, CA – January 16, 2018 – Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for hypertension, arthritis, pain and oncology, announced today that the Company has entered into a binding agreement with Autotelic Bio Inc., to enter into a license of Marina’s IT-103 Read More

Scroll Up